Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
A consensus on the definition of profound autism, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 5 July.
A consensus on the definition of profound autism, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 5 July.
‘Completely new learning mechanism’ drives navigation in fruit flies
The neuromodulator octopamine, the insect counterpart to norepinephrine, helps flies get their bearings in an unfamiliar environment.
‘Completely new learning mechanism’ drives navigation in fruit flies
The neuromodulator octopamine, the insect counterpart to norepinephrine, helps flies get their bearings in an unfamiliar environment.
How to use artificial intelligence to strengthen scientific processes and scholarly output
As AI-driven systems are integrated into all aspects of science, we need to make sure that they read and write to a shared data and knowledge space.
How to use artificial intelligence to strengthen scientific processes and scholarly output
As AI-driven systems are integrated into all aspects of science, we need to make sure that they read and write to a shared data and knowledge space.